TET Systems Enters Into Agreement With AMC/STW

TET Systems (TSH), the Academic Medical Center (AMC), and Technology Foundation STW have entered into an assignment agreement. Scientists at the AMC have previously developed a series of reverse transactivators with improved properties.

Under the terms of the agreement, AMC and STW assign the rights to the eight patent applications covering these new TET transactivators to TSH for commercialisation.

Ernst Boehnlein, CEO of TET Systems, said: “We are very pleased to sign this agreement with AMC and STW. Since TET Systems was established in 2004, all relevant IP covering the Tet Technology was in one hand and could be offered to our licensees as a package.

“With the acquisition of these patent applications from AMC and STW, we broadened our IP portfolio and the rights to the core Tet Technology are again unified and can now be offered to our existing licensees and new interested parties.

“TET Systems has been continuously growing its number of licensees and users of the Tet Technology over the past years. From now on, interested parties can again do ‘one-stop shopping’ for the relevant Tet Technology.”

Joris Heus of Technology Transfer Office at AMC, said: “We are excited to enter into this partnership with TET Systems as it opens the way to broad use of our improved transactivators in the scientific community, but also in the biotech and pharma industry.

“The existing scientific relationship between our researchers at AMC and the inventors of the Tet Technology formed the basis for the new IP generated at AMC and led to this agreement with TET Systems.”